PTGX Protagonist Therapeutics
- 33.390
- -0.960-2.79%
- 33.390
- 0.0000.00%
Protagonist Therapeutics News
We Think Some Shareholders May Hesitate To Increase Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Compensation
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $45
JMP Securities analyst Jonathan Wolleben maintains $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success ra
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $38
H.C. Wainwright analyst Douglas Tsao maintains $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate o
Express News | Protagonist Presents Updated Long-Term Findings From Rusfertide Phase 2 REVIVE Study At EHA2024, Demonstrating Sustained Hematocrit Control
Protagonist Reports Updated Long Term Results From Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit control , decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia
Express News | Protagonist Therapeutics Inc : JP Morgan Raises Target Price to $39 From $37
Protagonist Therapeutics(PTGX.US) Officer Sells US$1.23 Million in Common Stock
$Protagonist Therapeutics(PTGX.US)$ Officer PATEL DINESH V PH D sold 35,000 shares of common stock on Jun 7, 2024 at an average price of $35.19 for a total value of $1.23 million.Source: Announcement
Protagonist Therapeutics(PTGX.US) Director Sells US$280K in Common Stock
$Protagonist Therapeutics(PTGX.US)$ Director Waddill William D. sold 8,000 shares of common stock on Jun 7, 2024 at an average price of $35 for a total value of $280K.Source: Announcement What is stat
Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing
Dinesh V Patel, Director, President and CEO, on June 07, 2024, sold 35,000 shares in Protagonist Therapeutics (PTGX) for $1,231,650. Following the Form 4 filing with the SEC, Patel has control over a
Has Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Form 144 | Protagonist Therapeutics(PTGX.US) Director Proposes to Sell 280K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 7, $Protagonist Therapeutics(PTGX.US)$ Director WILLIAM D WADDILL intends to sell 8,000 shares of its common stock on Jun 7, with a total market value of approximately $280
Form 144 | Protagonist Therapeutics(PTGX.US) Insider Proposes to Sell 1.18 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 7, $Protagonist Therapeutics(PTGX.US)$ Insider Dinesh Patel intends to sell 35,000 shares of its common stock on Jun 7, with a total market value of approximately $1.18 mil
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
NEWARK, CA / ACCESSWIRE / May 31, 2024 / Protagonist Therapeutics, Inc. today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open labe
Express News | HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $38 Price Target
Buy Rating Affirmed for Protagonist Therapeutics on Strong Financials and Promising Clinical Trials
Protagonist Therapeutics, Inc. Just Recorded A 173% EPS Beat: Here's What Analysts Are Forecasting Next
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. Statutory revenue of US$255m and earnings o
Protagonist Therapeutics Is Maintained at Market Outperform by JMP Securities
Protagonist Therapeutics Is Maintained at Market Outperform by JMP Securities
Protagonist Therapeutics Price Target Raised to $45.00/Share From $42.00 by JMP Securities
Protagonist Therapeutics Price Target Raised to $45.00/Share From $42.00 by JMP Securities
Express News | JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45
Analysis
Price Target
No Data
